ATAI Life Sciences NV (FRA:9VC) Long-Term Capital Lease Obligation : €2.39 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Long-Term Capital Lease Obligation?

ATAI Life Sciences NV's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €2.39 Mil.

ATAI Life Sciences NV's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (€0.73 Mil) to Dec. 2024 (€0.70 Mil) but then increased from Dec. 2024 (€0.70 Mil) to Mar. 2025 (€2.39 Mil).

ATAI Life Sciences NV's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (€0.04 Mil) to Dec. 2023 (€0.91 Mil) but then declined from Dec. 2023 (€0.91 Mil) to Dec. 2024 (€0.70 Mil).

ATAI Life Sciences NV Long-Term Capital Lease Obligation Historical Data

The historical data trend for ATAI Life Sciences NV's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Long-Term Capital Lease Obligation Chart

ATAI Life Sciences NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.04

0.91

0.70

ATAI Life Sciences NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.83	0.78	0.73	0.70	2.39

ATAI Life Sciences NV (FRA:9VC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

ATAI Life Sciences NV Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

ATAI Life Sciences NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ATAI:USA ATAI:Mexico 9VC:Germany

Address

Wallstrasse 16, Berlin, BB, DEU, 10179

Website

https://www.atai.life

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

ATAI Life Sciences NV Headlines

No Headlines